The Pacific Northwest Udall Center (PANUC) is a collaborative enterprise among physicians and scientists at Oregon Health &Science University and the University of Washington that will focus considerable experience and expertise on cognitive impairment in patients afflicted with Parkinson's disease (PD). The Administrative and Outreach Core for PANUC has overall responsibility for the goal of producing an integrated and collaborative multidisciplinary center of excellence that promotes cutting-edge research advances in PD, and integrates effectively with local support and advocacy groups. The Director and Administrator, in full collaboration with the Executive Committee, will coordinate and integrate PANUC components, activities, and resources;solicit and review pilot project applications;foster productive interactions with other scientists and communities in the Pacific Northwest to assure progress in scientific and educational initiatives;assure compliance with human subjects, animal welfare, scientific integrity, and financial policy requirements of the NIH, UW and OHSU;provide timely transmissions of appropriate datasets to the PD Data Organizing Center (PD- DOC);collaborate fully with the Coriell Institute for submission to the NINDS Human Genetics Repository;and help train the next generation of researchers focused on PD.
The Pacific Northwest Udall Center (PANUC) will focus considerable experience and expertise on cognitive impairment in patients afflicted with Parkinson's disease (PD). The Administrative and Outreach Core for PANUC will facilitate this by producing and supporting an integrated and collaborative multidisciplinary center of excellence that promotes cutting-edge research advances in PD.
|Smulders, Katrijn; Dale, Marian L; Carlson-Kuhta, Patricia et al. (2016) Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism Relat Disord 31:3-13|
|Wang, Liyong; Maldonado, Lizmarie; Beecham, Gary W et al. (2016) DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet 2:e72|
|Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102|
|Mata, Ignacio F; Davis, Marie Y; Lopez, Alexis N et al. (2016) The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet 171:925-30|
|Costa-Mallen, Paola; Zabetian, Cyrus P; Hu, Shu-Ching et al. (2016) Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna) 123:1319-1330|
|Moelter, Stephen T; Weintraub, Daniel; Mace, Lauren et al. (2016) Research consent capacity varies with executive function and memory in Parkinson's disease. Mov Disord 31:414-7|
|Cholerton, Brenna; Larson, Eric B; Quinn, Joseph F et al. (2016) Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 186:500-6|
|Davis, Marie Y; Johnson, Catherine O; Leverenz, James B et al. (2016) Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol 73:1217-1224|
|Costa-Mallen, Paola; Zabetian, Cyrus P; Agarwal, Pinky et al. (2016) Response to the letter ""Haptoglobin phenotype and Parkinson disease risk"" by Delanghe et al. Parkinsonism Relat Disord 22:110-1|
|Crane, Paul K; Gibbons, Laura E; Dams-O'Connor, Kristen et al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 73:1062-9|
Showing the most recent 10 out of 151 publications